15,360,254 Common Stock of Onconova Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2014.
January 19, 2014
Share
15,360,254 Common Stock of Onconova Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2014. These Common Stock will be under lockup for 180 days starting from 24-JUL-2013 to 20-JAN-2014.
Details:
The officers, directors and certain of the stockholders holding an aggregate of 15,360,254 shares have agreed that without the prior written consent of Citigroup Global Markets Inc., they will not dispose of or hedge any shares of common stock for a period of 180 days from the date of the prospectus.
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
TRAWS PHARMA, INC. 
